GLP-1 diabetes drugs linked to up to 68% higher hair loss risk. The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds. Although the absolute risk is low, awareness of this potential effect may help inform shared treatment decisions, the researchers say.
- Ponto de atenção: diabetes.
- Ponto de atenção: drugs.
- Ponto de atenção: linked.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
